Newsroom
Press Releases
2022
- Late-breaking Data Demonstrate AHA/ACC Guideline-directed CCTA + FFRCT Precision Pathway is Superior to Traditional Testing
- HeartFlow Receives FDA 510(k) Clearance for its Plaque Analysis and RoadMap™ Analysis
- HeartFlow Announces Late Breakers Presentation at the 2022 American Heart Association (AHA) Scientific Sessions
- Presented at SCCT - New Plaque Clinical Data Provides Additional Insights on Anatomy and Physiology in Clinical Decision Making for Patients
- HeartFlow Appoints Monica Tellado as CFO
- HeartFlow Announces CEO Transition
- HeartFlow Announces Mutual Termination of Business Combination Agreement
- HeartFlow Appoints Timothy Barabe to its Board of Directors
2021
- HeartFlow Files for FDA Clearance of Next Generation Product Offering to Help Evaluate the Presence of Narrowings and Plaque in the Coronary Arteries
- HeartFlow Appoints Dr. Wayne J. Riley to its Board of Directors
- CMS Sets National Payment Rate for the HeartFlow Analysis in Doctors’ Offices and Imaging Centers
- HeartFlow Analysis is First AI-Enabled Technology to be Recognized by the American College of Cardiology and American Heart Association Guidelines as Important Tool in Diagnosing and Treating Heart Disease
- HeartFlow Announces Enrollment of First Two Patients in REVEALPLAQUE Trial
- HeartFlow Holding, Inc. Provides Selected Preliminary Second Quarter 2021 Financial Results and Updated Guidance for Full Year 2021
- HeartFlow Announces Enrollment of First Three Patients in FUSION Trial
- HeartFlow to Present at the Morgan Stanley Global Healthcare Conference
- HeartFlow Joins The Board Challenge as Newest Pledge Partner
- HeartFlow Appoints John Farquhar as Chief Operating Officer
- HeartFlow, the Leader in Precision Heart Care, Announces Merger with Longview Acquisition Corp. II to Become a Publicly Traded Company
- Late-Breaking Data Confirm the Accuracy of the HeartFlow Planner in Modeling Post-PCI Outcomes
- New 10-Year Data Demonstrate Superiority of the HeartFlow Analysis in Predicting Long-Term Outcomes in Patients with Coronary Artery Disease
- HeartFlow Announces Completion of Patient Enrollment in the PRECISE Trial
- HeartFlow and MedAxiom Announce Collaboration to Improve Care Delivery for Patients with Coronary Artery Disease
- NICE Renews Support for Use of AI-powered HeartFlow Analysis in Heart Disease Diagnosis
- New Medicare Local Coverage Determinations Published for the HeartFlow Analysis
- NHS England and NHS Improvement mandate adoption of AI-powered HeartFlow Analysis to fight coronary heart disease
2020
- New JAMA Network Open Publication Demonstrates the Coronary CT-HeartFlow Analysis Pathway is ‘Dominant’ Compared to Stress Testing in Cost-Effectiveness Analysis
- HeartFlow Appoints Cybersecurity Expert Julie Cullivan to its Board of Directors
- HeartFlow Highlights Two Presentations at the 2020 American Heart Association Virtual Meeting
- HeartFlow Applauds Healthcare Stakeholders’ Push for Change in How Coronary Artery Disease is First Diagnosed
- New Data Highlight a Significant Increase in Cardiovascular Treatment Efficiency when the HeartFlow Analysis is Incorporated into the Diagnostic Pathway
2019
- HeartFlow Announces FDA Clearance for HeartFlow Planner
- NHS England to Extend Reimbursement for the HeartFlow Analysis through Innovation and Technology Payment (ITP) Program
- Use of HeartFlow Planner Leads to Change in Treatment Strategy in Nearly Half of Patients with Coronary Heart Disease
- Late-Breaking Data Reinforces How the HeartFlow Analysis Can Help Physicians Precisely Stratify Heart Disease Patients and Deliver More Personalized Care
- Fast Company Names HeartFlow One of the World’s Most Innovative Companies
- HeartFlow Survey: Fewer than 1/3 of Americans Know Biggest Health Threat
- New JACC Publication Reinforces Value of a Coronary CTA + HeartFlow Analysis- Guided Pathway for Diagnosing Heart Disease
2018
- HeartFlow Initiates PRECISE Randomized Clinical Trial
- HeartFlow Receives National Reimbursement Approval in Japan
- HeartFlow Analysis Enables Physicians to Confidently and Safely Differentiate Patients in Need of Invasive Treatment and Patients Who Can be Managed Medically for Coronary Artery Disease
- NHS Hospitals Turn to Deep Learning and Advanced Algorithms to Fight Heart Disease
- HeartFlow Announces New Commercial Coverage with UnitedHealthcare, Largest Health Insurer in U.S.
- HeartFlow Analysis Demonstrates Highest Diagnostic Performance for Detecting Heart Disease Compared to Other Non-Invasive Tests
- NHS England to Provide Innovation and Technology Payment (ITP) to Drive Adoption of HeartFlow Analysis in the United Kingdom
- HeartFlow Announces Collaborative Research Agreement with Imperial College London
- HeartFlow Enters into Licensing Agreement with Cedars-Sinai for Coronary Plaque Assessment Technology
- HeartFlow Completes Series E Financing, Securing $240 Million